Table 5.

Statistical analysis of patient characteristics of RFS data

		Univariate analysis		Multivariate analysis
		p–value	HR [95%CI]	p–value	HR [95%CI]
Age		0.007	1.011 [1.003–1.019]	0.006	1.012 [1.004–1.021]
Gender (female vs. male)		< 0.001	0.632 [0.550–0.726]	0.038	0.806 [0.657–0.988]
Smoking history (+ vs. –)		< 0.001	1.519 [1.319–1.748]	0.552	0.938 [0.761–1.157]
Operation time		< 0.001	1.003 [1.002–1.004]	< 0.001	1.002 [1.001–1.003]
Invasion
	Lymphatic vessel invasion (+ vs. –)	< 0.001	3.123 [2.706–3.605]	0.002	1.330 [1.113–1.590]
	Vascular invasion (+ vs. –)	< 0.001	3.206 [2.779–3.698]	< 0.001	1.377 [1.155–1.643]
	Pleural invasion (+ vs. –)	< 0.001	2.574 [2.243–2.954]	0.448	1.070 [0.899–1.274]
Adenocarcinoma predominance
AIS + MIA			control		control
Lepidic		0.01	1.694 [1.132 – 2.533]	0.678	1.100 [0.702 – 1.722]
Acinar + Papillary + Variants		< 0.001	3.952 [2.783–5.611]	0.012	1.686 [1.124 – 2.530]
Solid + Micropapillary		< 0.001	7.041 [4.820–10.285]	< 0.001	2.221 [1.421—3.472]
EGFR status (+ vs. –)		0.205	0.902 [0.768–1.058]
Adjuvant chemotherapy (+ vs. –)		< 0.001	0.481[0.420—0.537]	0.016	0.812 [0.686—0.962]
Clinical stage
	Stage IA		control		control
	Stage IB	< 0.001	1.802 [1.535—2.115]	0.332	1.099 [0.908—1.329]
	Stage IIA	< 0.001	3.097 [2.481—3.866]	0.19	1.191 [0.917—1.546]
	Stage IIB	< 0.001	3.916 [2.913—5.266]	0.024	1.500 [1.055—2.135]
	Stage IIIA	< 0.001	5.774 [4.505—7.401]	0.017	1.454 [1.069—1.978]
Pathological stage
	Stage IA		control		control
	Stage IB	< 0.001	2.556 [2.097—3.116]	< 0.001	1.888 [1.459—2.442]
	Stage IIA	< 0.001	5.767 [4.621—7.197]	< 0.001	3.482 [2.613—4.640]
	Stage IIB	< 0.001	7.042 [5.316—9.328]	< 0.001	3.953 [2.737—5.710]
	Stage IIIA	< 0.001	10.288 [8.462—12.508	< 0.001	5.681 [4.247—7.600]